<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We performed a prospective randomized trial of antithoracic duct lymphocyte globulin (ATDLG), HLA-haploidentical marrow, and <z:chebi fb="3" ids="50113">androgen</z:chebi> (regimen <z:chebi fb="81" ids="2365,53554">ABA</z:chebi>) versus <z:chebi fb="3" ids="50113">androgen</z:chebi> alone (concurrent STANDARD care controls) in 42 newly diagnosed individuals with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="81" ids="2365,53554">ABA</z:chebi> patients also were matched with patients from our preceding study (historical STANDARD care controls) </plain></SENT>
<SENT sid="2" pm="."><plain>Supportive care and pretreatment patient characteristics were the same in <z:hpo ids='HP_0000001'>all</z:hpo> groups </plain></SENT>
<SENT sid="3" pm="."><plain>By life table analysis, 76% of patients receiving <z:chebi fb="81" ids="2365,53554">ABA</z:chebi> are alive at 2 yr compared to 31% of the concurrent control group (p less than 0.002 versus <z:chebi fb="81" ids="2365,53554">ABA</z:chebi>) and 19% of the historical controls (p less than 0.0001 versus <z:chebi fb="81" ids="2365,53554">ABA</z:chebi>) given STANDARD care </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="81" ids="2365,53554">ABA</z:chebi> patients had greater hematologic improvement than either control group (p less than 0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>However, improvement with <z:chebi fb="81" ids="2365,53554">ABA</z:chebi> was often incomplete </plain></SENT>
<SENT sid="6" pm="."><plain>Toxicity of ATDLG was considerable but manageable </plain></SENT>
<SENT sid="7" pm="."><plain>Further studies to determine the mechanism of action and active component(s) of <z:chebi fb="81" ids="2365,53554">ABA</z:chebi> are indicated </plain></SENT>
</text></document>